Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AGN:CC - Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

AGN:CC - Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

Algernon Pharmaceuticals Inc.

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease.

Moreau tells Proactive the patent, which is titled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis”, is based around its kidney disease program with the drug NP-251 or Repirinast. This is the company’s first allowance notice received from the US patent office.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-receives-notice-of-allowance-for-us-patent-for-drug-repirinast-and-nash-161132949

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...